Is Smart for Life (SMFL) $4.30, a Bargain Post Reverse Split?

We Think Yes..! With the year just finished ringing in $17.8 million in revenues, versus a market capitalization of...

Maxim Group Targets 175% Gain in Society Pass (SOPA) to $2.75.

If we average out the two most recent price targets this month, we come out with a potential gain of 337% and...

Hidden Gem and a Monster in the Making? Beasley Broadcast Group (BBGI) $0.80

If They Simply Changed Their Name to Beasley Internet Group, it Could be Revalued 3-Fold Higher. We...

Report: Think Equity Updates Society Pass (SOPA). $6.00 Price Target.

Think Equity: Society Pass (Nasdaq: SOPA) – Path to Profitability NEW YORK, NY, March 14, 2023 (GLOBE NEWSWIRE) --...

Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF.

Going Short the Market. No Long Dissertation, No Rush. Market Risk Has Appeared, With Minimal Upside, So Time To Act.

Interview: Rokas Sidlauskas, Marketing Director of Society Pass (SOPA)

Shares Roadmap to Expand the Society Pass (SoPa Group) Ecosystem in South East Asia. Related News

Meet Dennis Nguyen CEO of Start-Up Investor, the Society Pass (Symbol: SOPA)

See a Dazzling Presentation! Society Pass (SOPA) has quickly acquired 8 companies since going public in late 2021,...

Freedom Holding (FRHC) Acquires LD Micro From SRAX, Inc

Purchase brings pre-eminent small-cap platform to the Freedom family Freedom U.S. Markets, LLC, a wholly-owned subsidiary of Freedom Holding Corp....

EyeOnChannel.com

Eye on Channel is a digital video giant that connects millions of viewers to targeted and preferred demographics in destinations including Boston,...

Institutional Analyst: Our #1 Internet Company, Society Pass (Nasdaq: SOPA), Holds Appeal for Both...

Press Release: February 28, 2023 07:30 ET | Source: Society Pass Incorporated New York,...

Latest article

Asia-Pacific: A Region of Stability Amidst Economic Uncertainty

Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...

Hepion (HEPA) Back in the Spotlight, Gains 230% in May.

Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...

Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...

A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...